Bliss Biopharmaceutical (Hangzhou) Co., Ltd

A little over two months into 2025 and two Chinese drug makers have reaped the successes of moving their first-in-class pipeline innovations onto the domestic market, while two others have encountered

Although financings of over $100m have become something of a rarity for Chinese biotechs, venture capital and private equity firms, as well as pharma companies, have recently made sizeable cash inject

大家好！欢迎来到中国生物制药热点直播间！ 我是杨主编，负责Scrip和PinkSheet中国业务，今天我们讨论的热点是ASCO美国临床肿瘤学会年会正在芝加哥如火如荼进行。 今天来到直播间的除了我的同事，Dexter严，还有一位嘉宾，Leon唐均博士。他从芝加哥ASCO现场连线，来和我们一起聊一聊2023年的ASCO上的你不可不知道的热点和趋势！ 说起ASCO，最热门的就是一些热门靶点和热门公司的进

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Gilead Takes On XinThera’s Preclinical